Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Return on Sales (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Return on Sales for 7 consecutive years, with 1.26% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 4420.0% to 1.26% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.4% through Dec 2025, up 97.0% year-over-year, with the annual reading at 1.46% for FY2025, 99.0% up from the prior year.
  • Return on Sales hit 1.26% in Q4 2025 for BridgeBio Pharma, up from 1.53% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.09% in Q1 2024 to a low of 433.5% in Q3 2022.
  • Historically, Return on Sales has averaged 79.2% across 5 years, with a median of 44.02% in 2023.
  • Biggest YoY gain for Return on Sales was 111312bps in 2021; the steepest drop was -40886bps in 2021.
  • Year by year, Return on Sales stood at 18.06% in 2021, then crashed by -330bps to 77.61% in 2022, then crashed by -42bps to 110.09% in 2023, then soared by 59bps to 45.46% in 2024, then soared by 97bps to 1.26% in 2025.
  • Business Quant data shows Return on Sales for BBIO at 1.26% in Q4 2025, 1.53% in Q3 2025, and 1.66% in Q2 2025.